ConductScience.org, home

Paper19187

Clinical consequences of polymorphic acetylation of basic drugs.

Drayer DE and 1 other. Clin Pharmacol Ther, 1977. Cited by 150 papers, by iCite.

Cite this record

ConductScience Library. Clinical consequences of polymorphic acetylation of basic drugs. Papers, record 19187. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19187

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinical consequences of polymorphic acetylation of basic drugs.
PubMed
Journal
Clin Pharmacol Ther
PubMed
Year
1977
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
150
iCite
Relative citation ratio, by iCite
5.47
iCite
Revised in PubMed
2019-05-09
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Drayer DED E
2Reidenberg MMM M

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Pharmaceutical PreparationsMajor topic
Polymorphism, GeneticMajor topic
Acetylation
Antibodies, Antinuclear
Biotransformation
Chemical and Drug Induced Liver Injury
Humans
Hydralazine
Isoniazid
Lupus Erythematosus, Systemic
Phenelzine
Phenotype
Procainamide
Sulfasalazine

Source PubMed

Download CSV of topics

Cited by33

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 150 citations.

PMIDTitleJournalYearIn PapersSource
31964788N-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N-Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment.Antimicrob Agents Chemother2020https://conductscience.org/library/papers/31964788PubMed
24467436Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.Br J Pharmacol2014https://conductscience.org/library/papers/24467436PubMed
19968662Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients.Clin Exp Immunol2010https://conductscience.org/library/papers/19968662PubMed
15568141The effects of acute ethanol intake on isoniazid pharmacokinetics.Eur J Clin Pharmacol2004https://conductscience.org/library/papers/15568141PubMed
12844326Therapeutic drug monitoring of antiarrhythmic drugs.Clin Pharmacokinet2003https://conductscience.org/library/papers/12844326PubMed
10225813
Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years.
Ann Rheum Dis1999https://conductscience.org/library/papers/10225813PubMed
9131488N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism.J Pharmacokinet Biopharm1996https://conductscience.org/library/papers/9131488PubMed
8261714Individual variation in first-pass metabolism.Clin Pharmacokinet1993https://conductscience.org/library/papers/8261714PubMed
8103355Clinical significance of genetic influences on cardiovascular drug metabolism.Cardiovasc Drugs Ther1993https://conductscience.org/library/papers/8103355PubMed
7247454Hepatic acetylator phenotype in porphyria cutanea tarda.Arch Dermatol Res1981https://conductscience.org/library/papers/7247454PubMed
7059437A simple pharmacokinetic method for separating the three acetylation phenotypes: a preliminary report.Br J Clin Pharmacol1982https://conductscience.org/library/papers/7059437PubMed
7059436Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects.Br J Clin Pharmacol1982https://conductscience.org/library/papers/7059436PubMed
7047041Clinical pharmacokinetics of hydralazine.Clin Pharmacokinet1982https://conductscience.org/library/papers/7047041PubMed
7037261Drug metabolites in renal failure: pharmacokinetic and clinical implications.Clin Pharmacokinet1981https://conductscience.org/library/papers/7037261PubMed
6951172Relationship between the genetically determined acetylator phenotype and DNA damage induced by hydralazine and 2-aminofluorene in cultured rabbit hepatocytes.Proc Natl Acad Sci U S A1982https://conductscience.org/library/papers/6951172PubMed
6759093Pharmacologically active metabolites of drugs and other foreign compounds. Clinical, pharmacological, therapeutic and toxicological considerations.Drugs1982https://conductscience.org/library/papers/6759093PubMed
6721993A rapid method for determination of acetylation phenotype using dapsone.Br J Clin Pharmacol1984https://conductscience.org/library/papers/6721993PubMed
6721992A simple test for acetylator phenotype using caffeine.Br J Clin Pharmacol1984https://conductscience.org/library/papers/6721992PubMed
6131820Acetylation, deacetylation and acyltransfer.Environ Health Perspect1983https://conductscience.org/library/papers/6131820PubMed
3882287Inhibition of pokeweed mitogen-induced B cell differentiation by compounds containing primary amine or hydrazine groups.Clin Exp Immunol1985https://conductscience.org/library/papers/3882287PubMed

See all 33 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19187

GET https://conductscience.org/api/papers/v1/19187/cited_by?page=2